JP2006501240A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501240A5
JP2006501240A5 JP2004531017A JP2004531017A JP2006501240A5 JP 2006501240 A5 JP2006501240 A5 JP 2006501240A5 JP 2004531017 A JP2004531017 A JP 2004531017A JP 2004531017 A JP2004531017 A JP 2004531017A JP 2006501240 A5 JP2006501240 A5 JP 2006501240A5
Authority
JP
Japan
Prior art keywords
formulation
injection
site
unacceptable
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004531017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501240A (ja
JP4729306B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/025573 external-priority patent/WO2004017897A2/en
Publication of JP2006501240A publication Critical patent/JP2006501240A/ja
Publication of JP2006501240A5 publication Critical patent/JP2006501240A5/ja
Application granted granted Critical
Publication of JP4729306B2 publication Critical patent/JP4729306B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004531017A 2002-08-20 2003-08-14 アリピプラゾール錯体の製剤と方法 Expired - Fee Related JP4729306B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40471302P 2002-08-20 2002-08-20
US60/404,713 2002-08-20
PCT/US2003/025573 WO2004017897A2 (en) 2002-08-20 2003-08-14 Aripiprazole complex formulation and method

Publications (3)

Publication Number Publication Date
JP2006501240A JP2006501240A (ja) 2006-01-12
JP2006501240A5 true JP2006501240A5 (enExample) 2006-06-08
JP4729306B2 JP4729306B2 (ja) 2011-07-20

Family

ID=31946748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004531017A Expired - Fee Related JP4729306B2 (ja) 2002-08-20 2003-08-14 アリピプラゾール錯体の製剤と方法

Country Status (32)

Country Link
US (8) US7115587B2 (enExample)
EP (1) EP1542668B1 (enExample)
JP (1) JP4729306B2 (enExample)
KR (1) KR101043866B1 (enExample)
CN (1) CN100335047C (enExample)
AR (2) AR040887A1 (enExample)
AT (1) ATE428423T1 (enExample)
AU (1) AU2003269965B2 (enExample)
BR (1) BR0313602A (enExample)
CA (1) CA2495864C (enExample)
CY (1) CY1110331T1 (enExample)
DE (1) DE60327225D1 (enExample)
DK (1) DK1542668T3 (enExample)
ES (1) ES2322953T3 (enExample)
GE (1) GEP20063996B (enExample)
HR (1) HRP20050149B1 (enExample)
IL (1) IL166623A (enExample)
IS (1) IS2878B (enExample)
MX (1) MXPA05001865A (enExample)
MY (1) MY140793A (enExample)
NO (1) NO333458B1 (enExample)
NZ (1) NZ537995A (enExample)
PE (1) PE20040895A1 (enExample)
PL (1) PL212428B1 (enExample)
PT (1) PT1542668E (enExample)
RS (1) RS51903B (enExample)
RU (1) RU2342931C2 (enExample)
SI (1) SI1542668T1 (enExample)
TW (1) TWI307626B (enExample)
UA (1) UA79984C2 (enExample)
WO (1) WO2004017897A2 (enExample)
ZA (1) ZA200501064B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170705A1 (en) * 2001-03-08 2004-09-02 Dusan Miljkovic Compositions and methods for non-insulin glucose uptake
JP4729306B2 (ja) * 2002-08-20 2011-07-20 ブリストル−マイヤーズ スクイブ カンパニー アリピプラゾール錯体の製剤と方法
DE602004017342D1 (de) * 2003-10-23 2008-12-04 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
CA2550726A1 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
GB2442366A (en) * 2005-04-13 2008-04-02 Elan Pharma Int Ltd Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
ES2341996T3 (es) * 2005-06-03 2010-06-30 Elan Pharma International Limited Formulaciones de mesilato de imatinib en forma de manoparticulas.
US20090036406A1 (en) * 2005-06-13 2009-02-05 Takeda Pharmaceutical Company Limited Injection
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
MX2008006888A (es) 2005-11-28 2008-09-30 Marinus Pharmaceuticals Formulas y metodos para la manufactura y uso de la ganaxolona.
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
CN101322709B (zh) * 2007-06-12 2011-03-02 成都康弘药业集团股份有限公司 一种含有阿立哌唑的药物组合物及其制备方法
HUE036214T2 (hu) 2007-07-31 2018-06-28 Otsuka Pharma Co Ltd Eljárások aripiprazol-szuszpenzió és fagyasztva szárított készítmény elõállítására
US8501740B2 (en) * 2007-10-09 2013-08-06 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
KR20110007095A (ko) * 2008-03-21 2011-01-21 엘란 파마 인터내셔널 리미티드 이마티니브의 부위-특이적 전달을 위한 조성물 및 사용방법
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
HRP20171415T4 (hr) 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
WO2010151711A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
KR101125210B1 (ko) * 2009-09-11 2012-03-19 주식회사 대웅제약 아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
US20110140304A1 (en) * 2009-12-10 2011-06-16 Molecular Imprints, Inc. Imprint lithography template
WO2011163594A2 (en) 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
PL3156056T3 (pl) 2011-03-18 2024-04-29 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne zawierające estry sorbitanu
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
DK3702374T3 (da) 2012-02-15 2022-06-27 Cydex Pharmaceuticals Inc Fremsgangsmåde til fremstilling for cyclodextrin-derivater
NZ630703A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising glycerol esters
JP6471089B2 (ja) 2012-03-19 2019-02-13 アルカームス ファーマ アイルランド リミテッド 脂肪酸エステルを含む医薬組成物
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR101571670B1 (ko) * 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
AU2013349388B2 (en) 2012-09-19 2018-06-28 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
GR1008186B (el) 2013-04-22 2014-05-08 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150086408A1 (en) * 2013-09-26 2015-03-26 General Electric Company Method of manufacturing a component and thermal management process
TWI734665B (zh) 2013-12-24 2021-08-01 維吉尼亞聯邦大學 氧化膽固醇硫酸鹽（ｏｃｓ）之用途
GR1008442B (el) 2014-01-16 2015-03-05 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
RU2688233C2 (ru) 2014-03-20 2019-05-21 Алкермес Фарма Айэленд Лимитед Препараты арипипразола, имеющие повышенные скорости впрыска
CN105078910B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
US10780099B2 (en) 2015-10-16 2020-09-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
CN105616344A (zh) * 2016-01-06 2016-06-01 万全万特制药江苏有限公司 阿立哌唑注射液及其制备方法
TWI815796B (zh) * 2016-08-02 2023-09-21 美商杜瑞克公司 包含５－膽甾烯－３，２５－二醇３－硫酸酯（２５ｈｃ３ｓ）或其醫藥上可接受之鹽及至少一種環狀寡醣的組成物，以及使用彼等之方法
JP2019524816A (ja) 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
TW201828938A (zh) 2016-11-18 2018-08-16 德商艾庫里斯抗感染治療有限公司 以改質的環糊精及酸化劑為基底之經脒取代之β-內醯胺化合物的新穎調配物，其製備方法及作為抗微生物醫藥組合物之用途
JP6603815B2 (ja) * 2017-11-21 2019-11-06 積水化学工業株式会社 皮膚外用剤
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
CA3158280A1 (en) 2019-12-06 2021-06-10 Alex Aimetti Ganaxolone for use in treating tuberous sclerosis complex
JP2023551145A (ja) * 2020-11-18 2023-12-07 ベクソン バイオメディカル，インク． 医薬化合物の錯化剤塩製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
JP2893175B2 (ja) * 1988-10-31 1999-05-17 大塚製薬株式会社 カルボスチリル誘導体
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
GB9713149D0 (en) * 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
JP4729306B2 (ja) * 2002-08-20 2011-07-20 ブリストル−マイヤーズ スクイブ カンパニー アリピプラゾール錯体の製剤と方法
EP1562546A1 (en) 2002-10-25 2005-08-17 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension

Similar Documents

Publication Publication Date Title
JP2006501240A5 (enExample)
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
JP2005520778A5 (enExample)
NO20014519D0 (no) Apomorfin- og sildenafilpreparat
JP2013522303A5 (enExample)
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
JP2005524663A5 (enExample)
JP2005537234A5 (enExample)
JP2015524444A5 (enExample)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
PL2043637T3 (pl) Sposoby i leki do podawania ibuprofenu
DE60235178D1 (de) Darreichungsformen mit verlängerter wirkstofffreisetzung
JP2018526460A5 (enExample)
FI3840753T3 (fi) Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
JP2013518124A5 (enExample)
ATE546136T1 (de) Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln
JP2003528919A5 (enExample)
JP2002540148A5 (enExample)
RU2010146309A (ru) Фармацевтическая композиция для лечения фибромиалгии
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
RU2004105675A (ru) Способ комплексного лечения язв роговицы
WO2008079818A3 (en) Intravenous administration of water soluble analgesic formulations
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
RU2005131943A (ru) Лечебные и/или профилактические средства для хронических болезней кожи